Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REPL

Replimune Group Inc

Sep 12 • 04:00PM ET

5.73

-0.28 -4.66 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX FATE SGMO KPTI ALVR PGEN ADAP ANIX ENTX

| Held by: VTI IWM XBI VXF IWN IBB FESM VTWO SCHA DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.38	Insider Own	17.98%	Shs Outstand	77.81M	Perf Week	-9.48%
Market Cap	447.26M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	-0.60%	Shs Float	64.02M	Perf Month	12.57%
Enterprise Value	120.25M	PEG	-	EPS next Q	-0.77	Inst Own	96.90%	Short Float	29.01%	Perf Quarter	-42.03%
Income	-280.22M	P/S	-	EPS this Y	3.09%	Inst Trans	4.12%	Short Ratio	2.04	Perf Half Y	-51.69%
Sales	0.00M	P/B	1.32	EPS next Y	41.03%	ROA	-55.79%	Short Interest	18.57M	Perf YTD	-52.68%
Book/sh	4.33	P/C	1.11	EPS next 5Y	22.85%	ROE	-73.44%	52W High	17.00 -66.29%	Perf Year	-44.58%
Cash/sh	5.17	P/FCF	-	EPS past 3/5Y	-10.73% -14.85%	ROIC	-68.51%	52W Low	2.68 113.81%	Perf 3Y	-70.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.48% 6.39%	Perf 5Y	-75.11%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-1.07%	Oper. Margin	-	ATR (14)	0.51	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.94	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.00	Recom	2.78
Dividend Gr. 3/5Y	- -	Current Ratio	6.94	EPS Q/Q	-21.89%	SMA20	0.80%	Beta	0.47	Target Price	7.00
Payout	-	Debt/Eq	0.23	Sales Q/Q	-	SMA50	-15.21%	Rel Volume	0.15	Prev Close	6.01
Employees	479	LT Debt/Eq	0.21	Earnings	Aug 07 BMO	SMA200	-41.96%	Avg Volume	9.09M	Price	5.73
IPO	Jul 20, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.57% -	Trades		Volume	1,334,076	Change	-4.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-23-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-23-25	Downgrade	BMO Capital Markets	Outperform → Underperform	$2
Jul-23-25	Downgrade	Barclays	Overweight → Equal Weight	$3
Jul-22-25	Downgrade	Wedbush	Outperform → Neutral	$4
Jul-22-25	Downgrade	Piper Sandler	Overweight → Neutral	$3
Jul-22-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3
Jul-22-25	Downgrade	JP Morgan	Overweight → Neutral	$9
Jun-20-25	Initiated	Cantor Fitzgerald	Overweight
Aug-28-24	Initiated	ROTH MKM	Buy	$17
Apr-17-23	Resumed	Piper Sandler	Overweight	$44
Nov-19-21	Initiated	Piper Sandler	Overweight	$52
Oct-15-21	Resumed	BTIG Research	Buy	$60
Nov-17-20	Initiated	BTIG Research	Buy	$60
Nov-02-20	Initiated	Jefferies	Buy	$67
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy	$25 → $54
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral	$25
May-05-20	Initiated	Barclays	Overweight	$21
Sep-04-19	Initiated	ROTH Capital	Buy	$20
Jul-23-19	Initiated	Chardan Capital Markets	Buy	$28

Show Previous Ratings

Sep-12-25 04:42PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
Sep-04-25 12:56PM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (Business Wire)
09:30AM	Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman (PR Newswire)
Sep-03-25 04:18PM	Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman (PR Newswire)
Sep-02-25 08:00AM	Replimune Announces Type A Meeting Scheduled with FDA (GlobeNewswire) +9.26%
08:12AM	Loading…
Aug-28-25 08:12AM	Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman (Newsfile)
Aug-26-25 08:46AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire)
Aug-25-25 09:31AM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile)
Aug-20-25 05:04PM	Investors in Replimune Group, Inc. (REPL): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile) +6.67%
Aug-14-25 04:19PM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile) +5.11%
Aug-13-25 03:40PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
Aug-12-25 09:00AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPL (PR Newswire) +5.21%
Aug-11-25 11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz) -5.67%
Aug-07-25 08:00AM	Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 08:45AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire) +10.68%
09:52AM	Loading…
Aug-04-25 09:52AM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile) -24.87%
Jul-30-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +101.33%
Jul-23-25 03:46PM	REPL STOCK LOSS: BFA Law Notifies Replimune Group, Inc. Investors to Contact the Firm after Stock Drops 75% on FDA Response Letter (Newsfile) +18.89%
Jul-22-25 04:07PM	Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock (Investor's Business Daily) -77.24%
11:05AM	Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment (Barrons.com)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
07:00AM	Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma (GlobeNewswire)
Jul-11-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
Jun-01-25 10:00AM	Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-25 08:00AM	Replimune to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) +11.15%
May-23-25 03:03AM	Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
12:02AM	Q4 2025 Replimune Group Inc Earnings Call (Thomson Reuters StreetEvents)
May-22-25 07:00AM	Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
May-16-25 08:00AM	Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day (GlobeNewswire) +8.58%
May-09-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 03:26PM	Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma (Seeking Alpha)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-11-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.21%
Mar-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-25 08:00AM	Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.32%
Feb-07-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.88%
Jan-23-25 07:06AM	Replimune price target raised to $21 from $17 at H.C. Wainwright (TipRanks) +5.61%
Jan-21-25 01:01PM	Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy (GuruFocus.com) +16.86%
08:00AM	Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Jan-10-25 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-25 08:00AM	Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials (GlobeNewswire)
Dec-23-24 08:00AM	Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-24 11:55PM	Replimune Announces Pricing of Upsized Public Offering (GlobeNewswire) -11.19% +8.45%
07:09AM	Replimune Announces Proposed Public Offering (GlobeNewswire)
Nov-22-24 04:00PM	S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results (Benzinga) +35.11%
05:48AM	Replimune's stock surges 19% after-hours on FDA BLA submission (Investing.com)
Nov-21-24 04:05PM	Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway (GlobeNewswire)
Nov-12-24 08:00AM	Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-24 01:00PM	Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) (GlobeNewswire)
Nov-08-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-24 09:15AM	Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Oct-09-24 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
Oct-07-24 09:11PM	Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings (GuruFocus.com)
Oct-01-24 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.58%
Sep-15-24 09:45AM	Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-09-24 08:00AM	Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 (GlobeNewswire)
Sep-05-24 08:00AM	Stockholders Vote to Elect Madhavan Balachandran to Board of Directors (GlobeNewswire)
Aug-22-24 08:00AM	Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-14-24 04:33PM	Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy (Pharmaceutical Technology)
Aug-13-24 08:00AM	Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma (GlobeNewswire)
Aug-08-24 08:00AM	Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-30-24 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jun-13-24 08:30AM	Replimune Announces $100 Million Private Placement Financing (GlobeNewswire) +7.26%
Jun-07-24 09:03AM	Replimune (REPL) Gains on Positive Data From Melanoma Study (Zacks) +11.11%
08:00AM	Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-06-24 12:16PM	Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? (Benzinga) +27.88%
07:00AM	Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma (GlobeNewswire)
Jun-03-24 08:00AM	Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-24 05:00PM	Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.77%
May-16-24 01:53PM	REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 (InvestorPlace)
08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-07-24 05:00PM	Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-24 07:30AM	Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions (GlobeNewswire)
Mar-11-24 09:55AM	How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17% (Zacks)
Mar-08-24 12:00PM	What Makes Replimune Group, Inc. (REPL) a New Buy Stock (Zacks)
Mar-06-24 08:00AM	Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Replimune to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-23-24 09:55AM	Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High? (Zacks)
Feb-08-24 08:42AM	Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway (GuruFocus.com)
08:00AM	Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-16-24 03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire) -5.55%
Dec-28-23 08:00AM	Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 07:32AM	UPDATE 1-Replimune's skin cancer drug fails in mid-stage study (Reuters) -45.21%
07:10AM	CORRECTED-Replimune's skin cancer drug fails in mid-stage study (Reuters)
07:00AM	Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire)
Nov-08-23 09:10AM	Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research (GlobeNewswire) +6.56%
Nov-07-23 08:00AM	Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -15.85%
Nov-03-23 07:30PM	Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -9.37%
Oct-17-23 03:00AM	Tessellate BIO Emerges from Stealth (GlobeNewswire)
Sep-19-23 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.79%
08:00AM	Replimune Announces Appointment of Emily Hill as Chief Financial Officer (GlobeNewswire)
Sep-14-23 01:23PM	Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc (GuruFocus.com)
Aug-03-23 08:00AM	Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.69%
Aug-01-23 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hill Emily Luisa	Chief Financial Officer	Aug 15 '25	Sale	5.37	9,154	49,157	134,368	Aug 19 08:30 PM
Astley-Sparke Philip	Director	May 20 '25	Sale	8.06	32,279	260,169	1,405,071	May 22 09:47 PM
Xynos Konstantinos	Chief Medical Officer	May 20 '25	Sale	8.06	7,952	64,093	146,933	May 22 09:46 PM
Schwendenman Andrew	Chief Accounting Officer	May 20 '25	Sale	8.05	3,287	26,460	68,284	May 22 09:45 PM
Patel Sushil	Chief Executive Officer	May 20 '25	Sale	8.06	25,105	202,346	343,576	May 22 09:44 PM
Hill Emily Luisa	Chief Financial Officer	May 20 '25	Sale	8.05	2,535	20,407	143,522	May 22 09:44 PM
Sarchi Christopher	Chief Commercial Officer	May 20 '25	Sale	8.05	3,749	30,179	128,296	May 22 09:42 PM
Patel Sushil	Chief Executive Officer	Dec 16 '24	Sale	12.42	10,000	124,200	202,014	Dec 18 09:00 PM
Sushil Patel	Chief Strategy Officer	Dec 16 '24	Proposed Sale	12.57	15,000	188,550		Dec 16 04:48 PM
Xynos Konstantinos	Chief Medical Officer	Nov 18 '24	Sale	10.78	7,246	78,112	109,885	Nov 20 09:31 PM
Sarchi Christopher	Chief Commercial Officer	Nov 18 '24	Sale	10.78	5,207	56,131	87,045	Nov 20 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REPL

Replimune Group Inc

Upgrade your FINVIZ experience